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Abstract. 
Prostate cancer typically metastasizes to bones and regional lymph nodes. Generalized 
lymphadenopathy is a rare manifestation of metastatic prostate cancer. We report a case of 
prostate cancer in a 65-year-old male with initial presentation of generalized lymphadenopathy 
and no urinary symptoms. Lymph node biopsy revealed metastatic adenocarcinoma, and im-
munohistochemical staining was positive for prostate-specific antigen (PSA) compatible with a 
prostatic origin. Directed biopsy confirmed that the tumor originated in the prostate. Therefore, 
the prostate should be considered a possible origin of metastatic adenocarcinoma in men, and 
presentations consistent with generalized lymphadenopathy cannot exclude a diagnosis of 
prostate cancer. 
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中文摘要 
  攝護腺癌的轉移大多是以骨頭及局部淋巴結為主。全身性淋巴結腫大在轉移性攝護
腺癌上是非常罕見的。本個案為一位 65 歲診斷攝護腺癌的男性，以全身性淋巴結腫大為
初始表現且沒有任何相關泌尿道症狀。此病人的淋巴結切片報告為轉移性腺癌，其免疫
組織化學染色顯示攝護腺特異抗原為陽性，懷疑原發自攝護腺，最終以攝護腺切片確診
為攝護腺癌。因此，轉移性腺癌在男性一定要考慮攝護腺癌的可能，即便病人是以全身
性淋巴結腫大為表現的情況下，亦不能排除攝護腺癌的可能性。 
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 INTRODUCTION 
Prostate cancer is common in males. Urinary 
symptoms such as frequency, urgency, nocturia, and 
hesitancy are typical presentations in symptomatic 
patients. Bone and regional lymph nodes are the most 
common sites of metastasis. Lymphatic spread typi-
cally occurs in pelvic and abdominal retroperitoneal 
lymph nodes and rarely spreads to the supradiaphrag-
matic nodes [1]. Although the course of prostate can-
cer is usually predictable, sometimes the diagnosis 
may be challenging. We present a case uncharacteris-
tically presenting with generalized lymphadenopathy 
mimicking malignant lymphoma, which was ulti-
mately diagnosed with prostate cancer. 
 
CASE REPORT  
A 65-year-old male with a history of diabetes 
mellitus and pulmonary tuberculosis presented with a 
persistent but painless mass on the left neck for a 
month. He denied any other symptoms or discomfort, 
including fever, body weight loss, night sweating, 
poor appetite, dysphagia, sore throat, cough, hemop-
tysis, epistaxis, nasal obstruction, tinnitus. He first 
visited our ear, nose, and throat clinic, where physical 
examination showed firm and fixed bilateral supracla-
vicular lymph nodes 2-3 cm in size. Supraclavicular 
lymph node biopsy showed metastatic carcinoma of 
undetermined origin. Computed tomography scan 
from chest to liver (Figure 1) showed multiple lymph 
nodes over the cervical, bilateral supraclavicular, me-
diastinal, retrocrucial, and para-aortic spaces. Under a 
strong suspicion of lymphoma, another lymphadenec-
tomy was performed via video-associated thoracic 
surgery. The report confirmed a metastatic adenocar-
cinoma, and immunohistochemical staining was posi-
tive for prostate specific antigen (PSA) (Figure 2) and 
negative for TTF-1, CD5 and synaptophysin. Analysis 
of associated tumor markers revealed extremely high 
PSA (250.68 ng/mL) and free PSA (35.66 ng/mL) 
levels. He denied urinary symptoms such as difficult 
urination, painful urination, hematuria, urinary fre-
quency, and urgency. Digital rectal examination re-
vealed an enlarged prostate with a firm consistency 
and an irregular surface. A transrectal ultrasound- 
guided prostate biopsy confirmed the diagnosis of ad-
enocarcinoma (Gleason score 5+4=9) (Figure 3). Pel-
vic MRI for prostate cancer staging showed prostate 
carcinoma with extracapsular and seminal vesicle in-
vasion and bilateral common, internal, and external 
iliac metastatic lymphadenopathy. Bone scan revealed 
no metastatic bone lesions. The final diagnosis was 
prostate cancer, T3bN1M1a, stage IV. The patient was 
treated with bicalutamide and leuprorelin, and is cur-
rently being followed up at our outpatient clinic. 
    
DISCUSSION 
Prostate cancer is one of the most common cancers 
in males. PSA, a glycoprotein expressed by both nor-
mal and neoplastic prostate tissue, has been used for 
prostate cancer screening since the 1990s [2]. In addi-
tion to the PSA elevation seen with prostate cancer, 
there are other causes of an elevated PSA level, in-
cluding benign prostatic hyperplasia, prostate inflam-
mation/infection, and trauma, etc. Besides PSA, recent 
studies have demonstrated that the ratio of free-to- 
total PSA (f/t PSA) decreases in patients with prostate 
cancer and increases the specificity of cancer detec-
tion when total PSA is in the diagnostic gray zone (4 
~10 ng/mL) [3]. There is still a controversy regarding 
the optimal cut-off point of f/t PSA [4,5]. In our case, 
extremely high total PSA level (250.68 ng/mL) was 
noted. The elevated free PSA (35.66 ng/mL) and 
14.2% f/t PSA may be attributed to the extremely high 
level of total PSA and to prostatic enlargement.  
Most prostate cancer patients present with urinary  
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Figure 1. (A-C) Computed tomography images showed multiple metastatic lymph nodes over the    
bilateral cervical, bilateral supraclavicular, mediastinal, and paraaortic spaces 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Mediastinal lymph node biopsy results for the reported patient. (A) Photomicrograph showed 
neoplastic cells with round nuclei and prominent nucleoli consistent with a histopathological 
diagnosis of metastatic adenocarcinoma (H&E, 400x); (B) positive immunohistochemcial 
staining results for PSA (400x) 
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Figure 3. Prostate gland biopsy results supported his-
topathological diagnosis of adenocarcinoma, 
Gleason score 5+4=9 (H&E stain, 400x) 
 
 
symptoms such as frequency, urgency, nocturia, and 
hesitancy. Generalized lymphatic metastasis is a very 
rare manifestation of prostate cancer. Diagnosis is dif-
ficult not only because of its rare presentation of 
non-regional lymph node involvement, but also be-
cause of the absence of urinary symptoms and bone 
lesions. Literature review showed that metastases to 
the cervical and supraclavicular lymph nodes occurred 
in only about 0.4% and 0.28% of prostate cancer pa-
tients, respectively [6,7]. Another large study showed 
that 0.6% of patients with prostate carcinoma suffered 
from mediastinal metastases [8]. Additionally, a strong 
association between lymphatic and hematogenous 
metastases has been reported. For example, an autopsy 
study of 1,589 prostate cancer patients showed that 
simultaneous hematogenous spread was significantly 
more common in tumors with pelvic or paraaortal 
lymphatic metastases than in those without pelvic or 
paraaortal lymphatic metastases (84% versus 16%, 
respectively; P< 0.0001) [9]. Another retrospective 
study of 620 prostate cancer patients showed that 28 
patients had supradiaphragmatic lymphadenopathy. Of 
these, 25 (89%) had concurrent bone metastases. 
Therefore, supradiaphragmatic lymphadenopathy is 
strongly associated with concurrent bone metastases 
[10]. Our patient had the rare presentation of multiple 
metastatic lymph nodes in the absence of bone metas-
tasis. In conclusion, the diagnostic difficulty in the 
present case was that the patient presented with gener-
alized lymphadenopathy as the initial manifestation of 
prostate cancer without urinary symptoms and bone 
lesions. This case suggests that in males over 50 years 
of age who initially present with generalized lym-
phadenopathy and metastatic adenocarcinoma in the 
pathologic diagnosis, prostate cancer should be con-
sidered even in the absence of urinary symptoms and 
bone lesions. 
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